

IN THE SPECIFICATION:

Please replace paragraph number [0006] with the following rewritten paragraph:

[0006] Some cardiovascular therapies are designed to reduce the binding of Lp(a) by LDL receptors that are present on the interior walls of the arteries and include antioxidants to reduce swelling of the arteries. By way of example, U.S. Patent 5,650,148 to Rath et al. (hereinafter "Rath") describes a cardiovascular disease treatment composition which includes lysine or a pharmaceutically acceptable salt thereof, nicotinic acid, and ascorbic acid (*i.e.*, vitamin C). The lysine binds LDL receptors and, thus, prevents Lp(a) from binding such receptors, thereby reducing the negative-affects effects of Lp(a) on the arteries. Nicotinic acid and ascorbic acid are ~~antioxidants~~, antioxidants which reduce swelling of the arterial walls, thereby permitting more blood to flow through the arteries and, to some extent, reducing blood pressure.

Please replace paragraph number [0008] with the following rewritten paragraph:

[0008] Also, it is believed that such pathogens may damage the walls of blood vessels, which results in the binding of ~~lipoprotein(a) (Lp(a))~~ Lp(a) thereto.

Please replace paragraph number [0021] with the following rewritten paragraph:

[0021] The TEST EXAMPLE that follows provides data that shows the degree to which transfer factor causes an increase in the activity of natural killer cells, which are also referred to in the art as "cytotoxic T-lymphocytes" ("CTLs"), in attacking pathogens. ~~The test that was tests conducted as a~~ we chromium-51 (radioactive chromium, or ~~51-Cr~~) 51 Cr-assay assays. The tests were conducted *in vitro* on cell cultures, including *C. pneumoniae* and *H. pylori* bacterial cells and HSV-1-infected and HSV-2-infected mammalian cell lines. In the control, a fixed amount of natural killer cells was introduced into the cellular milieu along with a fixed amount of flour for a period of four hours, then the amount of chromium-51 that had been released was analyzed with a Beckman 2000 gamma counter. In a first set of test samples, the same, fixed

amount of natural killer cells was introduced into the cellular milieu along with a composition including bovine transfer factor in an amount equal to the amount of flour introduced into the control. A second set of test samples included the fixed amount of natural killer cells, as well as a composition including avian transfer factor in an amount equal to the amounts of flour in the control samples and the bovine transfer factor-containing composition in the first set of samples. The results follow:

TEST EXAMPLE				
Pathogen	<i>C. pneumoniae</i>	<i>H. pylori</i>	HSV-1	HSV-2
Additive	<u>chromium-51 counts per minute (cpm):</u>			
Flour	1323	1121	2017	1262
Bovine TF	2593	2499	2240	2473
percent increase	196%	223%	111%	196%
Avian TF	2553	1860	2985	2183
percent increase	193%	166%	148%	173%

Please replace paragraph number [0022] with the following rewritten paragraph:

[0022] The data shown in the TEST EXAMPLE indicate that both bovine transfer factor and avian transfer factor increase the activity of natural kill-~~cells~~ cells, reducing levels of *C. pneumoniae*, *H. pylori*, HSV-1 and HSV-2. It follows that the role-~~of~~ that each of these pathogens plays in cardiovascular disease would also be reduced or eliminated by therapy with mammalian transfer factor or nonmammalian transfer factor.

Please replace paragraph number [0024] with the following rewritten paragraph:

[0024] Since LDL receptor-binding elements are capable of occupying the sites on LDL receptors to which ~~lipoprotein(a) (Lp(a))~~ Lp(a) and LDL bind, LDL receptor-binding elements are useful for preventing Lp(a) from binding the LDL receptors and, thus, from additionally binding other components of the arterial walls, which binding is believed to contribute to cardiovascular disease.

Please replace paragraph number [0025] with the following rewritten paragraph:

[0025] Exemplary blood flow-enhancing elements, or vasodilators, that may be included in a composition of the present invention include, without limitation, arginine and arginine-containing compounds, such as magnesium arginate. Other blood flow-enhancing elements, such as niacinamide, may alternatively or additionally be included in such a composition. By way of example only, the blood flow-enhancing elements may target cardiovascular vessels located around the heart or improve blood flow in a more general fashion (*i.e.*, throughout the body of a treated subject). Combinations of ~~blood-flow~~ blood flow-enhancing elements that have different ~~blood flow~~ flow-enhancing characteristics may also be used in a composition that incorporates teachings of the present invention.

Please replace paragraph number [0031] with the following rewritten paragraph:

[0031] The following is an example of a composition that incorporates teachings of the present invention:

#### EXEMPLARY COMPOSITION

INGREDIENT	AMOUNT (per capsule)
<del>Transfer factor</del> <u>Factor</u> (Cardio-TF-XF™)	50 mg
Proprietary Blend	119.5 mg
Butcher's Broom (root) (22% sterolic heterosides)	
Ginkgo biloba (leaf) (24% ginkgo flavone glyeosides) glycosides, 6% terpene lactones)	
Hawthorn (flower and leaf) (1.8% rutin)	
Garlic (deodorized clove)	
Coenzyme Q <sub>10</sub>	
Red Rice Yeast Extract	
Reservatrol (from <i>Polygonum cuspidatum</i> )	
Ginger Oil	
Vitamin A (as <del>bete</del> <u>beta</u> carotene)	2,500 IU
Vitamin C (as magnesium dehydroascorbate, ascorbyl palmitate, and ascorbic acid)	200 mg
Vitamin E (as d-alpha tocopherol succinate)	100 IU
Niacin (as niacinamide)	20 mg
Vitamin B <sub>6</sub> (as pyridoxine hydrochloride)	2 mg
Folate (as folic acid)	400 mcg
Vitamin B <sub>12</sub> (as cyancobalamin)	8 mcg
Magnesium (as magnesium chloride, magnesium dehydroascorbate, magnesium arginate, and magnesium lysinate)	180 mg
Zinc (as zinc arginate)	10 mg
Selenium (as selenomethionine)	50 mcg
Copper (as copper glycinate)	2 mg
Potassium (as potassium citrate)	50 mg
TOTAL	367.508 mg

Please replace paragraph number [0032] with the following rewritten paragraph:

[0032] The EXEMPLARY COMPOSITION is marketed by 4Life Research, LLC, of Sandy, Utah, as ~~TRANSFER FACTOR CARDIO™~~ TF CARDIO®. The above-listed ingredients are contained within each capsule of the EXEMPLARY COMPOSITION.

Please replace paragraph number [0033] with the following rewritten paragraph:

[0033] In the EXEMPLARY COMPOSITION, the transfer factor is at least a part of an inflammation-reducing component or pathogen-reducing ~~component~~ component and comprises Cardio-TF-XF-XF<sup>TM</sup>, which includes transfer factor specific for HSV-I, HSV-II, *Chlamydia pneumoniae*, CMV, *Helicobacter Pylori*, and other pathogens (*e.g.*, those of the oral cavity) that are known to cause lesions and swelling in arterial walls. By enlisting the immune system of a treated subject in resisting such pathogens, the transfer factor component of a composition incorporating teachings of the present invention reduces a cause of inflammation and lesions that are at least partially responsible for many cardiovascular disorders. The transfer factors of Cardio-TF-XF<sup>TM</sup> are avian transfer factors which have been derived from the eggs of chickens.

Please replace paragraph number [0037] with the following rewritten paragraph:

[0037] Antioxidants that are included in the EXEMPLARY COMPOSITOIN include both hydrophilic and hydrophobic antioxidants, although compositions that include only hydrophilic or hydrophobic antioxidants are also within the scope of the invention. Vitamin E and beta-carotene, which are listed as components of the EXEMPLARY COMPOSITION, are examples ~~of a~~ of hydrophobic antioxidants. Vitamin E and beta-carotene are particularly useful in treating or preventing cardiovascular disease since they may be dissolved in fats, such as LDL cholesterol and Lp(a), and remain therein. Magnesium dehydroascorbic acid and ascorbic acid, both of which are forms of vitamin C, are examples of hydrophilic antioxidants that are included in the EXEMPLARY COMPOSITION. Another antioxidant that is included in the EXEMPLARY COMPOSITION, Coenzyme Q<sub>10</sub>, or "CoQ<sub>10</sub>," also acts as an electron-transport carrier.

Please replace paragraph number [0041] with the following rewritten paragraph:

[0041] The functions and ~~affects~~ effects (believed, theoretical, or actual) of each of the remaining components of the EXEMPLARY COMPOSITION on the cardiovascular health of a subject are well documented in the art.

Please replace paragraph number [0042] with the following rewritten paragraph:

[0042] Therapeutic methods which include use of a composition according to the present invention or combinations of the components thereof enlist the immune system of a treated subject to attack inflammation-causing pathogens, thereby reducing inflammation that may result in cardiovascular disorders. The immune system of a treated subject is enlisted by administering (*e.g.*, enterally or parenterally) a composition which includes one or more types of transfer factor, as described previously herein, to a subject. The manner in which transfer factor initiates activity by various components of a subject's immune system ~~are~~ is well known and documented in the art.

Please replace paragraph number [0047] with the following rewritten paragraph:

[0047] A female who had three abnormal electrocardiograms within a ~~three~~ three-month period received a normal electrocardiogram within two months of when she began taking four capsules of the EXEMPLARY COMPOSITION each day.